PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Analgesics and NSAIDs - Market size and forecast 2018-2023 • Corticosteriods - Market size and forecast 2018-2023 • Viscosupplements - Market size and forecast 2018-2023 • Others - Market size and forecast 2018-2023 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY TYPE • Ankle osteoarthritis • Hip osteoarthritis • Knee osteoarthritis • Shoulder osteoarthritis • Others PART 10: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bayer AG • GlaxoSmithKline plc • Johnson & Johnson Services, Inc. • Pfizer Inc. • Sanofi PART 15: APPENDIX • Research methodology • List of abbreviations PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Pipeline molecules for osteoarthritis Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Analgesics and NSAIDs - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Analgesics and NSAIDs - Year-over-year growth 2019-2023 (%) Exhibit 22: Corticosteriods - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Corticosteriods - Year-over-year growth 2019-2023 (%) Exhibit 24: Viscosupplements - Market size and forecast 2018-2023 ($ millions) Exhibit 25: Viscosupplements - Year-over-year growth 2019-2023 (%) Exhibit 26: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 27: Others - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Asia - Year-over-year growth 2019-2023 (%) Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: Bayer AG - Vendor overview Exhibit 49: Bayer AG - Business segments Exhibit 50: Bayer AG - Organizational developments Exhibit 51: Bayer AG - Geographic focus Exhibit 52: Bayer AG - Segment focus Exhibit 53: Bayer AG - Key offerings Exhibit 54: GlaxoSmithKline plc - Vendor overview Exhibit 55: GlaxoSmithKline plc - Business segments Exhibit 56: GlaxoSmithKline plc - Organizational developments Exhibit 57: GlaxoSmithKline plc - Geographic focus Exhibit 58: GlaxoSmithKline plc - Segment focus Exhibit 59: GlaxoSmithKline plc - Key offerings Exhibit 60: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 61: Johnson & Johnson Services, Inc. - Business segments Exhibit 62: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 63: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 64: Johnson & Johnson Services, Inc. - Segment focus Exhibit 65: Johnson & Johnson Services, Inc. - Key offerings Exhibit 66: Pfizer Inc. - Vendor overview Exhibit 67: Pfizer Inc. - Business segments Exhibit 68: Pfizer Inc. - Organizational developments Exhibit 69: Pfizer Inc. - Geographic focus Exhibit 70: Pfizer Inc. - Segment focus Exhibit 71: Pfizer Inc. - Key offerings Exhibit 72: Sanofi - Vendor overview Exhibit 73: Sanofi - Business segments Exhibit 74: Sanofi - Organizational developments Exhibit 75: Sanofi - Geographic focus Exhibit 76: Sanofi - Segment focus Exhibit 77: Sanofi - Key offerings Exhibit 78: Validation techniques employed for market sizing

Bayer AG GlaxoSmithKline plc Johnson & Johnson Services, Inc. Pfizer Inc. Sanofi